Medcura Launches a New Class of High-Performance, Antibacterial Hemostats Online and Through Leading Drugstores in the U.S. Market

Riverdale, Md.– Medcura, Inc., a commercial-stage life science and medical device company, announced today that Walmart.com, one of the world’s largest online retailers, will now be selling the Company’s antibacterial wound gel Rapid-Seal® through Walmart.com. This major retailer joins the growing list of other major retailers including Amazon and CVS that are selling this fast growing, first-aid product to quickly stop mild and nuisance bleeding.Rapid-Seal was cleared by the Food and Drug Administration (FDA) to provide rapid bleeding management and an antibacterial barrier helping to reduce infections. Rapid Seal is quickly becoming the consumer product of choice in this market segment where bandages can be ineffective, and powders are messy and can cause discomfort. Medcura custom designed this product to meet the market demand for a clear gel that can be easily and precisely applied to promote an environment for safe healing, especially for irregular injuries. By combining more exact delivery and highly effective wound sealing, Medcura’s gel provides the consumer with greater value.“Here is yet another major retailer who has elected to commercialize the Rapid-Seal product. Having Walmart.com join the ranks with Amazon and CVS to carry the product again demonstrates that our antibacterial bleeding management gel is gaining traction because it is so effective. They are just one of many other major retailers we expect to carry the product in the very near future,” said Medcura CEO Jim Buck. Medcura will soon announce that Rapid-Seal gel has been selected for shelf placement at yet another major retailer in early 2023, retailer name still undisclosed awaiting their preference for first making the announcement.Medcura combines the use of safe, inert, naturally abundant, low-cost ingredients with proprietary chemistry that can be delivered in easy-to-use formats that require no preparation or special handling. The Company continues to expand its product line now including, LifeFoam™, designated as a “Breakthrough Device” by the United States Food and Drug Administration (FDA), leading the expansion into internal military and surgical applications, while Medcura’s LifeGel™ Absorbable Surgical Hemostat has become the company’s premier product, entering global clinical trials in 2023.